The future of lymphoma diagnosis, prognosis, and treatment monitoring in countries with limited access to pathology services
- PMID: 37596119
- DOI: 10.1053/j.seminhematol.2023.07.004
The future of lymphoma diagnosis, prognosis, and treatment monitoring in countries with limited access to pathology services
Abstract
The world is moving towards precision medicine for cancer. This movement goes hand in hand with the development of newer advanced technologies for early, precise diagnosis of cancer and personalized treatment plans with fewer adverse effects for the patient. Liquid biopsy is one such advancement. At the same time, it has the advantage of minimal invasion and avoids serial invasive biopsies. In countries with limited access to pathology services, such as sub-Saharan Africa, liquid biopsy may provide an opportunity for early detection and prognostication of lymphoma. We discuss the current diagnostic modalities for lymphoma, highlighting the existing challenges with tissue biopsy, and how feasible it is for countries with limited pathology resources to leverage advancements made in the clinical application of liquid biopsy to improve lymphoma care.
Keywords: Burkitt lymphoma; Diffuse large B cell lymphoma; Hodgkin Lymphoma; Limited Resource; Liquid Biopsy.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. During the preparation of this work, the author(s) used Grammarly to improve the grammar and readability. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
